SEC-V: Studying the Effects of Cannabis on Vasculature
Study Details
Study Description
Brief Summary
Cannabis is commonly used globally. It is associated with psychiatric problems, but the effects on the cardiovascular system are unclear. In this project, the investigators plan to study the effects of cannabis on the cardiovascular system. This will be done by using a non-invasive test to measure blood vessel function and by using blood samples to measure inflammation. As a control for this project, the investigators would like to test the blood vessel function and inflammation levels of participants who do not use cannabis. This study will provide important information on the long term cardiovascular effects of cannabis.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
Cannabis is the most commonly used illicit drug in the world, but the investigators do not know the long-term effects on the cardiovascular system in humans. The investigators have data from cell culture and small animal studies that cannabis is toxic to the cardiovascular system. Recently legalized in Canada, the long-term effects of cannabis use on the cardiovascular system may not be apparent for several decades. The purpose of this study is to test the effect of cannabis use on the vascular system. Using a non-invasive test of vascular function, the investigators would like to assess the effects of cannabis on chronic cannabis users. The investigators would also like to test if cannabis use by smoking and/or vaping causes adverse cardiovascular effects acutely. Lastly, the investigators would like to test blood from chronic cannabis users for inflammatory cytokines, which could further support our hypothesis that cannabis damages the cardiovascular system via inflammation.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Chronic Cannabis Cohort For investigations on the effects of cannabis on the cardiovascular system, the investigators would like to recruit 50 participants with the following inclusion criteria: age: 19 to 80 males and females all ethnicities cannabis use at least 3-4 times per week or more in the past 6 months (50 volunteers, experimental group) no history of cardiovascular disease For investigations on the effects of cannabis on the cardiovascular system, the investigators will exclude cannabis users: that ingest cannabis containing cannabidiol (CBD) that are unable to provide a receipt for the cannabis product(s) they ingest that are unwilling to stop consuming soy products and/or genistein 48 hours prior to appointments. |
Other: Chronic Cannabis use
The investigators will test levels of inflammation and vascular dysfunction in participants who chronically use cannabis.
|
| Control Cohort For investigations on the effects of cannabis on the cardiovascular system, the investigators would like to recruit 50 participants with the following inclusion criteria: age: 19 to 80 males and females all ethnicities patients who do not use cannabis no history of cardiovascular disease For investigations on the effects of cannabis on the cardiovascular system, the investigators will exclude participants: that ingest cannabis that are unwilling to stop consuming soy products and/or genistein 48 hours prior to appointments. |
Outcome Measures
Primary Outcome Measures
- Inflammation [Baseline measurement.]
The investigators will measure the concentration of inflammatory cytokines using an Olink for chronic cannabis users and the control group.
- Endothelial function [Baseline measurement.]
The investigators will measure the reactive hyperaemia index (RHI) using an EndPAT device for both groups.
Secondary Outcome Measures
- Cholesterol Level [Baseline measurement.]
The investigators will measure lipid profile (total cholesterol, LDL, HDL, ratio) for both groups.
- BMI [Baseline measurement.]
The investigators will measure body-mass index or both groups.
- Blood pressure [Baseline measurement.]
The investigators will measure baseline blood pressure for both groups.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
age: 19 to 80
-
males and females
-
all ethnicities
-
cannabis use at least 3-4 times per week or more in the past 6 months (50 volunteers, experimental group)
-
patients who do not use cannabis (50 volunteers, control group)
-
no history of cardiovascular disease
Exclusion Criteria:
-
that ingest cannabis containing cannabidiol (CBD)
-
that are unable to provide a receipt for the cannabis product(s) they ingest
-
that are unwilling to stop consuming soy products and/or genistein 48 hours prior to appointments.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Lawson Health Research Institute
- Academic Medical Organization of Southwestern Ontario
- Canadian Cardiovascular Society
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- WCVP0001